Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer's disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another.

The end of the alliance doesn’t come as a huge surprise, given that both antibodies – anti-amyloid drug crenezumab and anti-tau candidate semorinemab – have both chalked up failed clinical ...